Ovarian cancer is the seventh most common gynaecologic malignancy seen in women.
Majority of the patients with ovarian cancer are diagnosed at the advanced stage making …

The diagnosis and treatment planning for newly diagnosed ovarian adenocarcinomas are
unique among solid cancers. Ovarian cancer is insidious in presentation with few sentinel …

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the
United States and is the country's fifth most common cause of cancer mortality in women. A …

This selection from the NCCN Guidelines for Ovarian Cancer focuses on the less common
ovarian histopathologies (LCOHs), because new algorithms were added for LCOHs and …

Paclitaxel, a class of taxane with microtubule stabilising ability, has remained with platinum
based therapy, the standard care for primary ovarian cancer management. A deeper …

Epithelial ovarian cancer is the most lethal of the gynecologic malignancies, largely due to
the advanced stage at diagnosis in most patients. Screening strategies using ultrasound and …

The natural history of ovarian cancer continues to be characterized by late-stage
presentation, metastatic bulky disease burden and stagnant mortality statistics, despite …

Cyclophosphamide remains one of the most successful and widely utilized antineoplastic
drugs. Moreover, it is also a potent immunosuppressive agent and the most commonly used …

We studied the whole-genome point mutation and structural variation patterns of 133 tumors
(59 high-grade serous (HGSC), 35 clear cell (CCOC), 29 endometrioid (ENOC), and 10 …

Objective To quantify the impact of complete cytoreduction to no gross residual disease on
overall survival among patients with advanced-stage ovarian cancer treated during the …